252 related articles for article (PubMed ID: 34906120)
1. Evaluation of a 55-gene classifier as a prognostic biomarker for adjuvant chemotherapy in stage III colon cancer patients.
Oki E; Shinto E; Shimokawa M; Yamaguchi S; Ishiguro M; Hasegawa S; Takii Y; Ishida H; Kusumoto T; Morita M; Tomita N; Shiozawa M; Tanaka M; Ozawa H; Hashiguchi Y; Ohnuma S; Tada S; Matsushima T; Hase K
BMC Cancer; 2021 Dec; 21(1):1332. PubMed ID: 34906120
[TBL] [Abstract][Full Text] [Related]
2. A Validation Study for Recurrence Risk Stratification of Stage II Colon Cancer Using the 55-Gene Classifier.
Shinto E; Oki E; Shimokawa M; Yamaguchi S; Ishiguro M; Morita M; Kusumoto T; Tomita N; Hashiguchi Y; Tanaka M; Ohnuma S; Tada S; Matsushima T; Hase K
Oncology; 2020; 98(8):534-541. PubMed ID: 32235113
[TBL] [Abstract][Full Text] [Related]
3. Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population-based study.
Alwers E; Jansen L; Bläker H; Kloor M; Tagscherer KE; Roth W; Boakye D; Herpel E; Grüllich C; Chang-Claude J; Brenner H; Hoffmeister M
Mol Oncol; 2020 Feb; 14(2):363-372. PubMed ID: 31816156
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study.
Tougeron D; Mouillet G; Trouilloud I; Lecomte T; Coriat R; Aparicio T; Des Guetz G; Lécaille C; Artru P; Sickersen G; Cauchin E; Sefrioui D; Boussaha T; Ferru A; Matysiak-Budnik T; Silvain C; Karayan-Tapon L; Pagès JC; Vernerey D; Bonnetain F; Michel P; Taïeb J; Zaanan A
J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26839356
[TBL] [Abstract][Full Text] [Related]
5. Microsatellite Instability and Adjuvant Chemotherapy in Stage II Colon Cancer.
Koenig JL; Toesca DAS; Harris JP; Tsai CJ; Haraldsdottir S; Lin AY; Pollom EL; Chang DT
Am J Clin Oncol; 2019 Jul; 42(7):573-580. PubMed ID: 31166206
[TBL] [Abstract][Full Text] [Related]
6. Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.
Klingbiel D; Saridaki Z; Roth AD; Bosman FT; Delorenzi M; Tejpar S
Ann Oncol; 2015 Jan; 26(1):126-132. PubMed ID: 25361982
[TBL] [Abstract][Full Text] [Related]
7. Improving clinical management of colon cancer through CONNECTION, a nation-wide colon cancer registry and stratification effort (CONNECTION II trial): rationale and protocol of a single arm intervention study.
van den Berg I; van de Weerd S; Roodhart JML; Vink GR; van den Braak RRJC; Jimenez CR; Elias SG; van Vliet D; Koelink M; Hong E; van Grevenstein WMU; van Oijen MGH; Beets-Tan RGH; van Krieken JHJM; IJzermans JNM; Medema JP; Koopman M;
BMC Cancer; 2020 Aug; 20(1):776. PubMed ID: 32811457
[TBL] [Abstract][Full Text] [Related]
8. Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX).
Kim JE; Hong YS; Kim HJ; Kim KP; Kim SY; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Kim JH; Kim TW
Ann Surg Oncol; 2017 May; 24(5):1289-1294. PubMed ID: 27853901
[TBL] [Abstract][Full Text] [Related]
9. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.
Roth AD; Delorenzi M; Tejpar S; Yan P; Klingbiel D; Fiocca R; d'Ario G; Cisar L; Labianca R; Cunningham D; Nordlinger B; Bosman F; Van Cutsem E
J Natl Cancer Inst; 2012 Nov; 104(21):1635-46. PubMed ID: 23104212
[TBL] [Abstract][Full Text] [Related]
10. Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis.
Rosati G; Galli F; Cantore M; Bergamo F; Banzi M; Zampino MG; Mattioli R; Cardellino GG; Ronzoni M; Di Bartolomeo M; Tamberi S; Marchetti P; Rimassa L; Corsi D; Bochicchio AM; Artioli F; Labianca R; Galli F; Rulli E; Bilancia D; Bregni G;
Oncologist; 2020 Jun; 25(6):e928-e935. PubMed ID: 31943506
[TBL] [Abstract][Full Text] [Related]
11. Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis.
Vernieri C; Galli F; Ferrari L; Marchetti P; Lonardi S; Maiello E; Iaffaioli RV; Zampino MG; Zaniboni A; De Placido S; Banzi M; Damiani A; Ferrari D; Rosati G; Labianca RF; Bidoli P; Frassineti GL; Nicolini M; Pavesi L; Tronconi MC; Buonadonna A; Ferrario S; Re GL; Adamo V; Tamburini E; Clerico M; Giordani P; Leonardi F; Barni S; Ciarlo A; Cavanna L; Gori S; Cinieri S; Faedi M; Aglietta M; Antista M; Dotti KF; Galli F; Di Bartolomeo M;
Oncologist; 2019 Mar; 24(3):385-393. PubMed ID: 30606884
[TBL] [Abstract][Full Text] [Related]
12. [Predictive and prognostic value of MSI phenotype in adjuvant colon cancer: Who and how to treat?].
Zaanan A; Taieb J
Bull Cancer; 2019 Feb; 106(2):129-136. PubMed ID: 30527814
[TBL] [Abstract][Full Text] [Related]
13. Combination of microsatellite instability and lymphocytic infiltrate as a prognostic indicator for adjuvant therapy in colon cancer.
Kumar S; Chang EY; Frankhouse J; Dorsey PB; Lee RG; Johnson N
Arch Surg; 2009 Sep; 144(9):835-40. PubMed ID: 19797108
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
Taieb J; Le Malicot K; Shi Q; Penault-Llorca F; Bouché O; Tabernero J; Mini E; Goldberg RM; Folprecht G; Luc Van Laethem J; Sargent DJ; Alberts SR; Emile JF; Laurent Puig P; Sinicrope FA
J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040692
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study.
Qin Q; Zhou AP; Yang L; Xu C; Sun YK; Zhang W; Wang JW; Zhong DS
J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33316771
[TBL] [Abstract][Full Text] [Related]
16. Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Cohen R; Taieb J; Fiskum J; Yothers G; Goldberg R; Yoshino T; Alberts S; Allegra C; de Gramont A; Seitz JF; O'Connell M; Haller D; Wolmark N; Erlichman C; Zaniboni A; Lonardi S; Kerr R; Grothey A; Sinicrope FA; André T; Shi Q
J Clin Oncol; 2021 Feb; 39(6):642-651. PubMed ID: 33356421
[TBL] [Abstract][Full Text] [Related]
17. ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.
Li P; Fang YJ; Li F; Ou QJ; Chen G; Ma G
Br J Cancer; 2013 Apr; 108(6):1238-44. PubMed ID: 23481186
[TBL] [Abstract][Full Text] [Related]
18. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin.
Zaanan A; Cuilliere-Dartigues P; Guilloux A; Parc Y; Louvet C; de Gramont A; Tiret E; Dumont S; Gayet B; Validire P; Fléjou JF; Duval A; Praz F
Ann Oncol; 2010 Apr; 21(4):772-780. PubMed ID: 19833818
[TBL] [Abstract][Full Text] [Related]
19. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and predictive significance of MSI in stages II/III colon cancer.
Saridaki Z; Souglakos J; Georgoulias V
World J Gastroenterol; 2014 Jun; 20(22):6809-14. PubMed ID: 24944470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
